Share-based Payment Arrangement, Expense of ImmunityBio, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ImmunityBio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,878,000, a 19% increase year-over-year.
  • ImmunityBio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $37,101,000, a 2.8% decline year-over-year.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $34,432,000, a 30% decline from 2023.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49,163,000, a 22% increase from 2022.
  • ImmunityBio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $40,179,000, a 30% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ImmunityBio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $37,101,000 $8,878,000 +$1,389,000 +19% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $35,712,000 $9,648,000 +$9,000 +0.09% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $35,703,000 $9,537,000 +$1,271,000 +15% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $34,432,000 $9,038,000 -$3,736,000 -29% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $38,168,000 $7,489,000 -$6,960,000 -48% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $45,128,000 $9,639,000 -$1,423,000 -13% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $46,551,000 $8,266,000 -$2,612,000 -24% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $49,163,000 $12,774,000 +$3,424,000 +37% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $45,739,000 $14,449,000 +$3,819,000 +36% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $41,920,000 $11,062,000 +$887,000 +8.7% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $41,033,000 $10,878,000 +$854,000 +8.5% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $40,179,000 $9,350,000 -$830,000 -8.2% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $41,009,000 $10,630,000 -$3,210,000 -23% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $44,219,000 $10,175,000 -$7,688,000 -43% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $51,907,000 $10,024,000 -$5,274,000 -34% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $57,181,000 $10,180,000 +$9,509,000 +1417% 01 Oct 2021 31 Dec 2021 10-K 19 Mar 2024 2023 FY
Q3 2021 $47,672,000 $13,840,000 +$13,126,000 +1838% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $34,546,000 $17,863,000 +$17,541,000 +5448% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $17,005,000 $15,298,000 +$14,818,000 +3087% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $2,187,000 $671,000 -$600,000 -47% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $2,787,000 $714,000 +$437,000 +158% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $2,350,000 $322,000 -$200,000 -38% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $2,550,000 $480,000 -$871,000 -64% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $3,421,000 $1,271,000 -$136,000 -9.7% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $3,557,000 $277,000 -$3,691,000 -93% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $7,248,000 $522,000 -$8,412,000 -94% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $15,660,000 $1,351,000 -$7,722,000 -85% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $23,382,000 $1,407,000 -$7,477,000 -84% 01 Oct 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
Q3 2018 $30,859,000 $3,968,000 -$4,746,000 -54% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $35,605,000 $8,934,000 -$447,000 -4.8% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $36,052,000 $9,073,000 -$945,000 -9.4% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $36,997,000 $8,884,000 -$2,382,000 -21% 01 Oct 2017 31 Dec 2017 10-K 25 Mar 2020 2019 FY
Q3 2017 $39,379,000 $8,714,000 -$9,955,000 -53% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $49,334,000 $9,381,000 -$13,974,000 -60% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018 2018 Q2
Q1 2017 $63,308,000 $10,018,000 -$10,544,000 -51% 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1
Q4 2016 $73,852,000 $11,266,000 -$10,125,000 -47% 01 Oct 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
Q3 2016 $83,977,000 $18,669,000 -$20,325,000 -52% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $104,302,000 $23,355,000 -$102,958,000 -82% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $207,260,000 $20,562,000 -$3,961,000 -16% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $211,221,000 $21,391,000 01 Oct 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
Q3 2015 $38,994,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $126,313,000 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $24,523,000 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1

ImmunityBio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $34,432,000 -$14,731,000 -30% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $49,163,000 +$8,984,000 +22% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $40,179,000 -$17,002,000 -30% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $57,181,000 +$54,994,000 +2515% 01 Jan 2021 31 Dec 2021 10-K 19 Mar 2024 2023 FY
2020 $2,187,000 -$1,234,000 -36% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $3,421,000 -$19,961,000 -85% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $23,382,000 -$13,615,000 -37% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
2017 $36,997,000 -$36,855,000 -50% 01 Jan 2017 31 Dec 2017 10-K 25 Mar 2020 2019 FY
2016 $73,852,000 -$137,369,000 -65% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
2015 $211,221,000 +$210,432,000 +26671% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $789,000 -$95,000 -11% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
2013 $884,000 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.